← Eichor
Study identifier: NCT05007561 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Understanding How Opioids Affect the Experiential and Neural Signatures of Social Experiences

Condition: Naltrexone · Placebo  ·  Sponsor: San Diego State University

PhaseEARLY_Phase 1
Planned participants210
Who can joinAll sexes, 18 Years to 25 Years
Healthy volunteersYes

About this study

The study is a randomized, placebo-controlled design with the opioid antagonist, oral naltrexone. Following random assignment, participants will take 50mg of naltrexone or placebo once a day for 7 days. On days 1 - 7, participants complete reports of their feelings of social connection and mood in order to assess more naturalistic feelings in response to opportunities for social connection outside of the laboratory setting. Additionally, at the end of each day, they complete a physical symptoms questionnaire. On the 7th day, participants will come to the SDSU MRI scanning facility to complete tasks designed to elicit feelings of social connection in the fMRI scanner. After the scan, feelings in response to the scanner tasks will be collected.

This description comes directly from the study's public registry record.

Talk to the study team

Tristen Inagaki, PhD  ·  6195941058  ·  tinagaki@sdsu.edu

Always discuss trial participation with your own doctor first.

Locations (1)

San Diego State UniversitySan Diego, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05007561